Production and Characterization of 188Re-C595 Antibody for Radioimmunotherapy of Transitional Cell Bladder Cancer
Andrea Murray,
Matthew S. Simms,
David P. Scholfield,
Rachel M. Vincent,
Graeme Denton,
Michael C. Bishop,
Michael R. Price and
Alan C. Perkins
Department of Medical Physics, Medical School, Queens Medical Centre, Nottingham; Department of Urology, City Hospital, Nottingham; and Cancer Research Laboratories, School of Pharmaceutical Sciences, University of Nottingham, Nottingham, United Kingdom

View larger version (16K):
[in a new window]
|
FIGURE 1. Affinity separation of 188Re-C595 antibody complex from high-molecular-weight contaminating material. Washing and elution of hybrid affinity column system were performed as follows: PBS (12 mL), 3 mol/L NaSCN (2 mL), and PBS (11 mL). Absorbance values at 280 nm (dashed line) and activity (solid line) of each fraction are plotted. AU = absorbance units.
|
|

View larger version (16K):
[in a new window]
|
FIGURE 2. Sephacryl S300 gel filtration analysis of affinity-purified 188Re-C595 antibody complex (solid line) measured as activity in counts per minute (cpm), unlabeled C595 antibody (dashed line) measured as absorbance at 280 nm, and 188Resodium perrhenate (dotted line) measured as activity in cpm. AU = absorbance units.
|
|

View larger version (75K):
[in a new window]
|
FIGURE 4. Tumor localization of 188Re-C595 in ex vivo model. (A) Postwashout gamma-camera image shows area of increased uptake on right-hand side of specimen. (B) Bladder was dissected to reveal area of tissue that had neoplastic appearance corresponding to hot spot on gamma-camera image (A). Presence of transitional cell carcinoma was confirmed by pathologic examination.
|
|

View larger version (73K):
[in a new window]
|
FIGURE 5. (A) Intravenous pyelogram shows large filling defect on left-hand side of bladder, which was confirmed as G3pT1 transitional cell carcinoma at operation. (B) Gamma-camera image shows localized uptake of 188Re-C595 complex at site of tumor.
|
|
Copyright © 2001 by the Society of Nuclear Medicine.